

 aaps
National 
Biotechnology
CONFERENCE

M
A
Y | **13-16**
2024

HILTON SAN FRANCISCO
UNION SQUARE
SAN FRANCISCO, CA

CALL FOR POSTER ABSTRACTS

AAPS SEEKS POSTER ABSTRACT SUBMISSIONS
THAT PRESENT DATA-DRIVEN, NOVEL RESEARCH
IN THE PHARMACEUTICAL SCIENCES.



ADVANCES IN DISCOVERY,
FORMULATION,
AND DELIVERY OF
NEW MODALITIES



NOVEL STRATEGIES
TO ADVANCE
BIOTHERAPEUTIC
DEVELOPMENT

TABLE OF CONTENTS

TRACKS	3
IMPORTANT DATES (all dates subject to change)	5
Poster Abstract Submissions	5
ABSTRACT AND POSTER POLICY	6
Permissions/Clearances	6
Registration Requirement for Participation and Publication	6
Posters Must Include the Accepted Abstract	6
ABSTRACT FORMAT	7
Acceptance Criteria	7
Common Causes for Rejection	7
Encore Presentations	8
Abstract Revisions	8
Notification of Receipt and Verification of Submission	8
SCREENING PROCESS	9
Notification of Acceptance/Rejection	9
Appeals	9
REGISTRATION REQUIREMENT	10
Registration Requirement	10
Change in Presenting Author	10
Poster Schedule	10
Cancellation Policy and Substitution	10
Abstract/Poster Withdrawal	10
POSTER FORMAT REQUIREMENTS	11
FREQUENTLY ASKED QUESTIONS	11
POSTER ABSTRACT TRACKS/ THEMES/KEYWORDS	12

TRACK-BASED PROGRAMMING

EACH ABSTRACT PROPOSAL MUST RELATE TO ONE OF THE FOLLOWING TWO TRACKS:

TRACK 1



ADVANCES IN DISCOVERY, FORMULATION, AND DELIVERY OF NEW MODALITIES

A tremendous rise in the biologics market has driven significant interest in their discovery and in using novel drug delivery systems to enable drug delivery via different routes. This track focuses on aspects of the discovery and development of biologics and new modalities. Submissions are invited on topics related to multi-specific antibodies, oligonucleotides, proteins, nanobodies, genes, RNA, peptides, cell-free manufactured proteins, vaccines, cells, and allogenic and synthetic cells. Discussions are encouraged on diverse strategies for the discovery, formulation, and delivery of these modalities to address unmet medical needs.

THEME 1:

Preformulation and Formulation Approaches for Biologics and New Modalities

Keywords: Preformulation, Formulation, Stability, CMC, Excipient, Impurities, Biologics

Explore the challenges associated with preformulation and formulation development of biologics and new modalities. In addition to the modalities mentioned above under Track 1, submissions related to screening and excipients selection, the impact of excipients on pharmacokinetics/pharmacodynamics (PK/PD), and stability are welcome. Discussions of CMC (Chemistry, Manufacturing, and Controls) issues related to the development of these modalities are encouraged.

THEME 2:

Drug Delivery for New Modalities and Therapies

Keywords: Drug Delivery, Gene Delivery, Vaccines, Cell Therapy, Personalized Medicine

This theme focuses on different strategies and challenges involved in the design of drug delivery systems, the delivery of biologics, and manufacturing challenges in the development of novel drug delivery systems. Topics such as nanoparticles, liposomes, hydrogels, ADCs (Antibody-Drug Conjugates), nano bots and devices, personalized medicines, cell-based therapies, and viral and non-viral gene delivery are the

primary focus. Submissions on advances in the delivery of genes, vaccines, and biotherapeutics via non-parenteral routes of administration (e.g., oral, topical, intravitreal, nasal, and inhalation) are encouraged.

THEME 3:

AI/ML in Drug Discovery and Development

Keywords: Artificial Intelligence, Synthetic Biology, Gene Editing, CRISPR, Discovery

This theme explores how Artificial Intelligence/Machine Learning (AI/ML), and big data are transforming the landscape of drug development and reducing discovery time and cost. Submissions are welcome on novel biotherapeutics developed using AI; AI-enabled gene-editing drugs; and the combination of AI, synthetic biology, and cell manufacturing as well as their impact on new drugs, novel design, and manufacturing processes. Topics to be covered include: CMC and regulatory issues; the use of AI in CMC and process development; decentralized manufacturing, risks, and benefits associated with using AI in drug discovery and development; and data integrity concerns.

TRACK-BASED PROGRAMMING CONTINUED

TRACK 2



NOVEL STRATEGIES TO ADVANCE BIOTHERAPEUTIC DEVELOPMENT

Advances in therapeutic development for targeted delivery, platform technology, high-content bioanalysis, and data science.

THEME 1:

Development Strategy for Novel Targeted Therapeutic Delivery

Keywords: Targeted Delivery, Bioanalysis, Pharmacokinetics

The field of targeted drug delivery is advancing with new modalities such as lipid nanoparticles, cell therapies, and gene therapeutics. Science is also gaining ground in the design of protein therapeutics tailored to deliver to specific tissues (examples: eye, tumor, and brain) and methods for bioanalysis. Discuss how pharmacokinetics, pharmacodynamics, and immunogenicity bioanalysis and data for tissue-targeted therapeutics can inform and advance therapeutic development.

THEME 2:

Advances in Analytical and Bioanalytical Platform Technology

Keywords: Instrumentation Platforms, Flow Cytometry, Multiplexing, Imaging, Data Science

The field of analytical platform technology is rapidly keeping pace with the emergence of new modalities such as oligonucleotides and cell-and-gene therapies, as well as the increasing need for more informative analytical evaluation of traditional therapeutics such as monoclonal antibodies and antibody drug conjugates. Discuss high-resolution instrumentation techniques, multiplexing, flow cytometry, imaging platforms, and other technology advancements. Submissions are also welcome related to the associated developments in data science that add

increased information to biodistribution, pharmacokinetics, immunogenicity, and pharmacodynamics analyses.

THEME 3:

High Content Bioanalysis

Keywords: MAPPS, In-Silico Prediction, Immunogenicity Prediction, Artificial Intelligence, Machine Learning, personalized medicine, Omics

High Content Bioanalysis in genomics, proteomics, metabolomics, and lipidomics, along with technologies to identify and measure biomarkers at the single cell level, combined with advances in data sciences (artificial intelligence) are exponentially evolving. Discuss case studies and platforms for high content bioanalysis for personalized medicine, novel -omic approaches, immunogenicity prediction, immunogenicity risk assessments, and digital biomarkers. Submissions are also welcome that explore evolving data science and artificial intelligence methodologies for analysis of large data sets.

IMPORTANT ABSTRACT DATES

POSTER ABSTRACT SUBMISSIONS



ALL DATES SUBJECT TO CHANGE

ABSTRACT AND POSTER POLICY

By submitting an abstract for presentation at the AAPS National Biotechnology Conference, you agree to abide by the conditions and policies provided below, as well as the decisions of the Abstract Screening Committee and AAPS staff.

Direct questions about this (NBC) policy to abstracts@aaps.org.

PERMISSIONS/CLEARANCES

AAPS recommends the designated presenting author submit the abstract. The submitter is responsible for obtaining the necessary permissions and clearances for all research, information, and graphics used in both the abstract and the poster, and the submitter will receive all abstract and poster-related communications. AAPS assumes no liability or responsibility for the publication of any material that is submitted.

Use of the AAPS logo in any abstract submission or poster presentation is STRICTLY PROHIBITED.

REGISTRATION REQUIREMENT FOR PARTICIPATION AND PUBLICATION

The presenting author is required to attend the meeting to present the poster. If the presenting author is unable to participate during the meeting, a coauthor is required to assume the responsibilities of the presenting author and present the poster. If no authors are able to participate in the meeting, a presenter may be appointed who is not an author of the abstract.

The presenting author or presenter is required to register either as a full-conference, one-day, exhibitor, or exhibit-hall-only attendee for the meeting by the Presenting Author Registration Deadline, or AAPS will withdraw the abstract/poster. Abstracts/posters that are withdrawn for any reason, including the failure of the author to show at their assigned presentation date and time, will not be published online or included in the poster collection.

Exhibitors who are presenting authors must complete their registrations by the Presenting Author Registration Deadline, even if they are using an exhibitor registration provided by their employer.

POSTERS MUST INCLUDE THE ACCEPTED ABSTRACT

Posters that are uploaded for presentation must include the accepted abstract, including all methods used and data resulting from the research. **The title of the poster must match, verbatim, the title of the accepted abstract.** The use of an AAPS poster template is required. All posters are presented digitally—no printed posters are allowed.

Omitting data from a poster presentation that was included in the submitted abstract is unethical. Authors and organizations violating these requirements will be subject to penalties including withdrawal of their abstract/poster and their being barred from submitting to any future AAPS meeting.

ABSTRACTS MUST BE SUBMITTED TO THE SUBMISSION WEBSITE BY 5:00 PM ET ON THE INDICATED DEADLINE DATE.

Abstracts submitted after this deadline or by different means will be rejected without review.

DATA SUPPORTING THE CONCLUSION OF THE ABSTRACT MUST BE DEVELOPED PRIOR TO SUBMISSION.

Abstracts stating that data will be developed between the time of submission and the time of the meeting will be rejected without review.



USE THE GOOGLE CHROME BROWSER TO SUBMIT YOUR ABSTRACT.

The submission system can be accessed at the [Submission Site](#).

To ensure receipt of all abstract-related correspondence, add the following addresses to your contact list:

support@conferenceabstracts.com
scorecard@cadmiumcd.com
abstracts@aaps.org
homricht@aaps.org
appeals@aaps.org
posters@aaps.org

ABSTRACT FORMAT

ACCEPTANCE CRITERIA

Acceptance of the abstract for poster presentation will be based on the concise, accurate presentation of new data. It is imperative that data is presented in the Results section so that AAPS scientific screeners can judge the scientific value of the abstract. Include all research information, data, charts, and graphs in your submission so that it can be screened in its entirety. Abstracts will be reviewed and scored based on the following:

- Is the CONCLUSION of the research data driven?
- How EXCITING/NOVEL will viewers find this research?
- How well does the RESEARCH incrementally advance its field?
- How well does the author's selected strategy for evaluating the HYPOTHESIS suit the project?

COMMON CAUSES FOR REJECTION

AAPS reviews each abstract to ensure it is qualified for consideration. Abstracts that do not meet the requirements outlined above are rejected. Causes for rejection include:

- Lack of data
- Acknowledgements were included in the abstract, preventing a blind review
- Affiliation or company name(s) were included in the abstract or in images, preventing a blind review (product names are permitted)
- Commerciality
- Inconsistent or ambiguous data
- Reviews of literature
- Lack of novelty or innovation
- Stating that data or information will be included in the poster presentation instead of including it in the abstract
- Previously published research
- Including previously published information in research without referencing the information in the abstract submission
- Failure to follow format guideline outlined (Purpose, Methods, Results, Conclusion, References, Acknowledgements, images)
- Failure to upload tables or charts (if used) as images as directed (Tables, charts, bulleted lists or numbered lists are not to be included in the text box for the Purpose, Methods, Results, or Conclusion. Tables, charts, bulleted lists or numbered lists must be uploaded as images—refer to the Abstract Format section.)
- Failure to submit one strong abstract instead of several abstracts presenting the same work. The submission of multiple abstracts covering the same or similar work is discouraged and may be rejected by the committee.

ABSTRACTS MUST CONTAIN THE FOLLOWING ELEMENTS

DATA, including all research information either in paragraph format or in charts and graphs. AAPS rejects any abstract that is not based on data.

TITLE in headline style: 200-character limit with no period at the end

AUTHORS: Limit of 13 authors

AFFILIATIONS: One affiliation per author

PURPOSE: paragraph format

METHODS: paragraph format

RESULTS: paragraph format

CONCLUSIONS: paragraph format

REFERENCES: Reference any research previously published in a journal and used in the abstract's research.

IMAGES in jpg format, no more than three (3). Do not include images in the Purpose, Methods, Results, or Conclusion sections.

TABLES, CHARTS, AND/OR BULLETED/NUMBERED LISTS:

No more than 3. Convert each to a jpg and upload into the Images section. Do not include tables, charts, bulleted lists, or numbered lists in the Purpose, Methods, Results, or Conclusion sections.

ACKNOWLEDGEMENTS, DISCLAIMERS, FUNDING, AND OTHER DISCLOSURE OR CONFLICT OF INTEREST STATEMENTS:

This area should include any disclaimers, acknowledgements, funding, and other disclosure or conflict of interest statements, such as ethics approvals for animal use or human participation, that would prevent a blind review. This information will not be available to reviewers during the review process.

ABSTRACT LENGTH AND IMAGES

Abstracts may contain **a maximum of 800 words and includes the Purpose, Methods, Results, and Conclusion sections.**

1 to 3 images in jpg format may be included.

Data tables must be uploaded as one of three possible images and not included in the abstract text boxes.

ENCORE PRESENTATIONS

AAPS accepts encore presentations, which are unpublished abstracts and posters that have been presented elsewhere. No abstract or resulting poster may be displayed at the National Biotechnology Conference or any other AAPS event without the review and approval of the Abstract Screening Committee, regardless of prior presentation elsewhere.

ABSTRACT REVISIONS

- Revisions can be made at any time **before the poster abstract submission deadline** listed under the important dates.
- If you revise your abstract submission, you must be sure to save your changes and click Submit. Failure to complete all the steps will result in an incomplete submission, and your abstract will not be sent to the Abstract Screening Committee. Revisions cannot be made after the poster abstract submission deadline.
- Author names and affiliation or company names will be published as submitted. Be sure you have the correct and current author information. No changes may be made after the submission deadline, including adding or removing authors.
- Proofread, spell-check, and make sure all authors are listed on your abstract before submitting, as the abstracts will be presented in conference materials exactly as they appear at the time of submission.

NOTIFICATION OF RECEIPT AND VERIFICATION OF SUBMISSION

- You will receive an immediate email confirmation of completion when you have successfully submitted the abstract. This notification only confirms receipt of your submission and is not a notification of acceptance.
- If you do not receive an immediate email confirmation, your submission is not complete. You will need to return to the submission site to complete the submission process.
- If you return to the submission site to review or make changes to your abstract for any reason, you must complete all submission steps again in order to be sure your abstract is successfully submitted.

TOP 4 REASONS ABSTRACTS ARE REJECTED

Each year, AAPS rejects a few dozen abstracts—many “without review,” which means the abstracts were not qualified for consideration and were never shown to a panel of scientific screeners.

HERE ARE THE TOP 4 REASONS THIS HAPPENS:

- 1. The abstract does not contain any data.**
AAPS will not accept an abstract that is not based on data that has already been developed.
- 2. The abstract is too commercial.**
AAPS welcomes research conducted by any scientist, but does not permit sales pitches.
- 3. The abstract does not follow the formatting and guidelines outlined in this document.**
- 4. The abstract contains author, company name, or affiliation, preventing a blind review process.**

SCREENING PROCESS

QUALIFIED ABSTRACTS are reviewed by a blind review panel of at least 3 scientists who score each abstract based on these questions:

QUESTION #1	QUESTION #2	QUESTION #3	QUESTION #4
Is the CONCLUSION of the research data driven?	How EXCITING / NOVEL will viewers find this research?	How well does the RESEARCH incrementally advance its field?	How well does the author's selected strategy for evaluating the HYPOTHESIS suit the project?

WARNING

Abstracts are screened during a blind review process. No author or affiliation names may be included in the abstract Title, Purpose, Methods, Results, or Conclusion sections or in uploaded images. Including this information in these areas will result in an automatic rejection of the abstract because a blind review would not be possible.

Authors of accepted abstracts and posters will abide by the decisions and instructions of AAPS. If authors fail to follow AAPS' policies and instructions, their abstract(s) and/or poster(s) will be removed from AAPS' displays. Authors may also have their acceptances rescinded and, in extreme cases, may see themselves and the organizations they represent barred from future meetings.

NOTIFICATION OF ACCEPTANCE/REJECTION

Notification of accept/reject and other pre-submission deadline correspondence will be sent to the submitting author. Once a poster abstract is accepted, additional communications will be sent to the designated presenting author.

APPEALS

Appeals based on proposed additions or changes to an abstract or poster that has already been submitted will be rejected without consideration by AAPS as these changes constitute a new abstract or poster.

To appeal the rejection or withdrawal of an abstract or poster, the submitting author must email the following to appeals@aaps.org within 5 business days of AAPS issuing the rejection:

1. Email Subject Line: Appeal [Abstract Submission ID Number]
2. Abstract title
3. Contact information for the submitter
4. Statement explaining on what grounds the author feels AAPS should reverse its decision

Appeals submitted by someone other than the submitter of the abstract, or by any means other than stated above, do not constitute an appeal and will be rejected without review.

Upon receiving a request for an appeal, the AAPS Screening Committee Chair will seat a Review Committee of three members. The Review Committee will:

1. Consider the policies and requirements for abstracts and posters as described in AAPS' materials
2. Review the abstract as submitted
3. Review the reasoning behind the rejection
4. Review the argument provided by the submitting author

The Review Committee will not consider any proposed changes to the abstract as submitted.

The final decision will be communicated to the author by email.

REGISTRATION REQUIREMENT

REGISTRATION REQUIREMENT

If selected for presentation, authors presenting posters must:

- Register as a full-conference, one-day, exhibitor, or exhibit-hall-only attendee for the 2024 AAPS National Biotechnology Conference by midnight ET on the **Presenting Author Registration Deadline** listed under important dates.
- The posters of authors who fail to register by the deadline will be withdrawn from AAPS' collection of posters.
- Coauthors may present in place of the presenting author if notification is made to AAPS at abstracts@aaps.org. The presenting coauthor must complete and pay for their registration before the change in presenting author can be made.
- A presenter who is not an author or coauthor of the abstract may present the poster if no authors are able to participate. Changes in the presenter or presenting author must be sent to AAPS at abstracts@aaps.org.
- Authors working in an exhibitor's booth may register as an exhibitor, but their registration must be completed by midnight ET on the **Presenting Author Registration Deadline** indicated under important dates.

CHANGE IN PRESENTING AUTHOR

All requests for a change in presenter or presenting author after the final submission deadline must be sent by the submitting author to AAPS at abstracts@aaps.org and include the Submission ID Number as well as the name and email address of the new presenter or presenting author. No authors may be added after the submission deadline.

POSTER SCHEDULE

AAPS will notify presenting authors of the scheduled day, time, and assigned poster number by email.

- If you do not receive notification, contact AAPS at abstracts@aaps.org for an update on the scheduling of your abstract.
- Notifications will be sent only to the designated presenting author.
- All posters are included in the collection and accessible online.

- Posters are presented in person. AAPS does not permit virtual presentation of posters under any circumstance.
- Authors are required to be present during the full 60 minutes of their scheduled poster session.
- Posters are presented digitally. Paper posters are not permitted.

CANCELLATION POLICY AND SUBSTITUTION

- All requests for refunds and/or substitutions must be submitted in writing and emailed to aaps.helpdesk@goeshow.com.
- Authors canceling their registration on/before April 10, 2024, will be refunded their registration fee minus an administration fee of \$100 for members/non-members, or \$50 for student/postdoc members.
- No refunds will be given for "no shows" or for cancellations received after April 10, 2024.
- Refunds will be credited back to the original credit card used for payment.
- Substitutions from the same company may be submitted in writing at any time without penalty. If the membership status of the substitute differs from that of the original registrant, a refund or additional charge at the current rate may apply.
- Membership cancellation requests must be sent in writing by email to membership@aaps.org within 30 days of the membership start date. AAPS membership cannot be transferred. This offer is not valid for individuals that have taken advantage of discounted member pricing during the current membership term.

ABSTRACT/POSTER WITHDRAWAL

The submitting author may withdraw their abstract or poster at any time.

To withdraw, send written notification to abstracts@aaps.org and include:

1. Submission ID Number (Assigned Poster Number if withdrawing after Poster Schedule is issued)
2. Abstract title
3. Names of authors
4. Contact information for the submitter

AAPS will acknowledge all withdrawal notifications by email.

Withdrawal is not complete until AAPS issues notification of withdrawal to the submitting author.

POSTER REQUIREMENTS

ALL POSTERS ARE PRESENTED IN A DIGITAL FORMAT.

1

Authors must format their posters using one of the PowerPoint templates provided by AAPS. Templates include instructions and format policies that must be followed in order to have a poster accepted for presentation.

2

The poster title must match the accepted abstract word-for-word/verbatim. No edits or changes are permitted.

3

The poster must describe all the methods used and data generated by the research. Omitting data from a poster that was described in the abstract is an ethical violation that may result in the poster being removed and the author and the organization represented by the author being barred from future meetings.

4

Authors of accepted abstracts and posters will abide by the decisions and instructions of AAPS. The posters of authors who fail to follow AAPS' policies and instructions will be removed from AAPS' online collection. Authors may also have their acceptance rescinded and, in extreme cases, may see themselves, and the organizations they represent, barred from future meetings.

5

Posters must be uploaded by the date indicated in the Important Dates section. AAPS recommends uploading posters as soon as they are complete. All posters are reviewed prior to display by AAPS to ensure proper formatting.

FREQUENTLY ASKED QUESTIONS



Do I have to be a member of AAPS to submit an abstract?

No. Membership is not required.



Can a paper previously presented be submitted?

Encore presentations are acceptable and do not need to be referenced as an encore presentation. Research that has been published in a journal is not allowed.



Who owns the copyright on the abstract and poster?

The author(s)* maintains copyright of the abstract and poster, including all proprietary rights other than copyrights, such as patent rights.

**The submitting author is responsible for all authors knowing that their names appear on the abstract.*



How will AAPS use my abstract?

If the abstract is accepted for poster presentation at the conference, the abstract will be displayed on the conference website/mobile app before, during, and after the meeting for a limited amount of time, and on the AAPS member website and the AAPS poster viewing site after the conference for one year.



How will AAPS use my poster?

If your abstract is accepted for poster presentation at the conference, your poster, which will include the abstract text plus other relevant information and graphics, will be available for display throughout the conference and on the AAPS poster viewing site after the conference for one year.



Will my poster be on the app or in the Proceedings?

Your abstract and poster will appear on the conference website, available to registrants only, and will be available on the AAPS poster viewing website after the meeting.

POSTER ABSTRACT TRACKS/ THEMES/KEYWORD(S)

(REVIEW GROUPS)

The 2024 AAPS National Biotechnology Conference has two tracks—each track has three themes.

SUBMITTED ABSTRACTS MUST RELATE TO A TRACK!

NOTE: In the submission site, the structure below; Track | Theme | Keyword(s) are referred to as Review Groups. You will be prompted to select the Review Group that best fits your abstract.

REVIEW GROUP (Track/Theme/Keywords) SELECTION PROCESS

1 Select the TRACK that best fits your research:



**ADVANCES IN DISCOVERY,
FORMULATION, AND DELIVERY
OF NEW MODALITIES**



**NOVEL STRATEGIES TO
ADVANCE BIOTECHNOLOGICAL
DEVELOPMENT**

2 Select the THEME.

3 Select the KEYWORD(S) that best fits your research.

TRACK

THEME

KEYWORDS



TRACK 1
**Advances in Discovery,
Formulation, and Delivery
of New Modalities**

THEME 1:
Preformulation and
Formulation Approaches
for Biologics and
New Modalities

- Biologics
- CMC
- Excipient
- Formulation
- Impurities
- Preformulation
- Stability



TRACK 1
**Advances in Discovery
Formulation, and Delivery
of New Modalities**

THEME 2:
Drug Delivery
for New Modalities
and Therapies

- Drug Delivery
- Cell Therapy
- Gene Delivery
- Personalized Medicine
- Vaccines



TRACK 1
**Advances in Discovery
Formulation, and Delivery
of New Modalities**

THEME 3:
AI/ML in Drug Discovery
and Development

- Artificial Intelligence
- CRISPR
- Discovery
- Gene Editing
- Synthetic Biology

continued on following page

POSTER ABSTRACT TRACKS/ THEMES/KEYWORD(S) (REVIEW GROUPS) CONTINUED

TRACK	THEME	KEYWORDS
 TRACK 2 Novel Strategies to Advance Biotherapeutic Development	THEME 1: Development Strategy for Novel Targeted Therapeutic Delivery	<ul style="list-style-type: none">- Targeted Delivery- Bioanalysis- Pharmacokinetics
 TRACK 2 Novel Strategies to Advance Biotherapeutic Development	THEME 2: Advances in Analytical and Bioanalytical Platform Technology	<ul style="list-style-type: none">- Instrumentation Platforms- Data Science- Flow Cytometry- Imaging- Multiplexing
 TRACK 2 Novel Strategies to Advance Biotherapeutic Development	THEME 3: High Content Bioanalysis	<ul style="list-style-type: none">- MAPPS- Artificial Intelligence- Immunogenicity Prediction- In Silico Prediction- Machine Learning- Omics- Personalized Medicine

